Faron Pharmaceuticals Reports Promising BEXMAB Trial Results

Faron Pharmaceuticals Oy (GB:FARN) has released an update.

Faron Pharmaceuticals has announced promising interim Phase 2 results from its BEXMAB trial, showing an 80% objective response rate in myelodysplastic syndrome (MDS) patients who previously failed hypomethylating agent treatments. This significant improvement in treatment outcomes could potentially extend the median overall survival of these patients from 5-6 months to approximately 13.4 months. The company plans to present detailed findings at the upcoming ASH Annual Meeting, signaling a potential breakthrough in cancer immunotherapy.

For further insights into GB:FARN stock, check out TipRanks’ Stock Analysis page.